Dr. Liao is currently Executive Vice President of Product Development and a member of the Board of Directors at United BioPharma (UBP). She served as the President of UBP during its formative stage from 2014 to 2018. Dr. Liao has over 35 years’ experience in the biopharmaceutical industry. Prior to joining UBP in January 2014, she was vice president of UBI, responsible for regulatory affairs for biological products and was a key member in UBI’s NIH-funded HIV Therapeutic Vaccine program. From 2003 to 2007, she was vice president of research & development and quality control for Hemispherix Biopharma, Inc., responsible for product development for natural leukocyte interferon (Alferon®) and therapeutic RNA (Ampligen®). She also served from 1983 to 2003 at Interferon Sciences, from a bench scientist with increasing responsibilities to vice president of research and development, where she directed all R&D projects in the major areas of protein biochemistry, cell biology, and molecular biology. Dr. Liao is accomplished in the development of therapeutic biological products, from research to preclinical testing, human clinical trials, and final approval by the US FDA and other regulatory agencies.
She received her B.S. in chemistry from National Tsing Hua University, in Taiwan, her M.S. and Ph.D. in physical biochemistry from Yale University. Dr. Liao completed postdoctoral training at Massachusetts Institute of Technology under the direction of Nobel Laureate Professor H. Gobind Khorana. She is the author of numerous publications and holds several patents in the area of alpha interferons.